Asensus Surgical Company Profile: Ownership and Products
Updated: 7 days ago
Asensus Surgical makes the Senhance surgical robot for laparoscopic surgery and has been a subsidiary of the German company KARL STORZ since August 2024. KARL STORZ paid USD 0.35 per share in cash. This profile sets out the ownership and products.
Asensus Surgical at a Glance
Fact | Detail |
Company | Asensus Surgical |
Headquarters | Research Triangle Park, North Carolina, USA |
Owner | KARL STORZ, since August 22, 2024 |
Price paid | USD 0.35 per share in cash |
Products | Senhance, on the market; LUNA, in development |
President and CEO at closing | Anthony Fernando |
Ownership
The merger with KARL STORZ Endoscopy-America closed on August 22, 2024. Asensus became a subsidiary of KARL STORZ, and its shares stopped trading on the NYSE American exchange.
KARL STORZ is a family-owned medical technology company founded in 1945 in Tuttlingen, Germany, and a major maker of endoscopes. It is in its third generation, has about 9,400 employees in more than 40 countries and reported sales of EUR 2.17 billion for 2023. Its chief executive is Karl-Christian Storz.
Products
Product | Status |
Senhance | First-generation surgical robot, on the market |
LUNA | Second-generation system, in development |
At the time of the closing, LUNA had not been submitted to or cleared by any regulator and was not for sale. Asensus describes its field as digital laparoscopy, using software that assists the surgeon during the operation.
Can You Invest in Asensus?
No longer. The shares were delisted when the acquisition closed, and the parent is a private family company.
What Is Not Covered
The founding year, earlier company names, employee numbers and sales are not stated in the source used, so they are left out.
Strengths and Challenges
Strengths
A parent with a strong position in endoscopy and operating room equipment.
A system already in clinical use.
Challenges
A low purchase price that reflects the difficulty it had as an independent company.
A next-generation system that still needs regulatory clearance.
Asensus Surgical FAQ
Who owns Asensus Surgical?
KARL STORZ, since August 22, 2024.
How much did KARL STORZ pay?
USD 0.35 per share in cash.
What does Asensus make?
The Senhance surgical robot; a second system, LUNA, is in development.
Is Asensus still publicly traded?
No. Its shares stopped trading when the acquisition closed.
